Home › Kanser sa Suso › Tennessee › Nashville
Pag-aaral pangklinika para sa Kanser sa Suso sa Nashville, TN
Isang pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Nashville. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Nagre-recruitPhase 3
- Tennessee Oncology, PLLC, Nashville
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of PHST001 in Advanced Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Nagre-recruitPhase 3
- Sarah Cannon Research Institute, Nashville
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Nagre-recruitPhase 2
- Sarah Cannon Research Institute (Nashville), Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Nagre-recruitPhase 2
- Tennessee Oncology, Greco-Hainsworth Center for Research, Nashville
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Nagre-recruitPhase 1
- Research Site, Nashville
IKS014 in Advanced Solid Tumors That Express HER2
Nagre-recruitPhase 1
- Tennessee Oncology, Nashville
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Nagre-recruitPhase 1
- Scri Oncology Partners, Nashville
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Nagre-recruitPhase 3
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0068), Nashville
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Nagre-recruitPhase 3
- Research Site, Nashville
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Nagre-recruitPhase 3
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- Vanderbilt-Ingram Cancer Center ( Site 0038), Nashville
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Nagre-recruitPhase 1/2
- Vanderbilt Ingram Cancer Center, Nashville
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Nagre-recruit
- Vanderbilt, Nashville
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Nagre-recruitPhase 3
- Clinical Trial Site, Nashville
- Clinical Trial Site, Mount Juliet · 15 mi ang layo
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Nagre-recruitPhase 3
- Sarah Cannon Research Institute SCRI, Nashville
- Nashville General Hospital, Nashville
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Nagre-recruitPhase 2
- Tennessee Oncology, Nashville
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Nagre-recruitPhase 3
- Tennessee Oncology, Nashville
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Nagre-recruitPhase 1/2
- Sarah Cannon Nashville, Nashville
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Nagre-recruitPhase 3
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
- Henry - Joyce Cancer Clinic, Nashville
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Nagre-recruitPhase 1/2
- Tennessee Oncology PLLC, Nashville
- Vanderbilt University Medical Center, Nashville
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Nagre-recruitPhase 2
- SCRI Oncology Partners ( Site 7000), Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Center, Nashville
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Nagre-recruitPhase 3
- Research Site, Nashville
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Nagre-recruitPhase 1/2
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Nagre-recruitPhase 3
- Vanderbilt University Medical Center, Nashville
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Nagre-recruitObservasyonal na pag-aaral
- Nashville General, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Nagre-recruitPhase 1/2
- Tennessee Oncology, Nashville
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Nagre-recruitPhase 1
- Sarah Cannon Research Institute/SCRI, Nashville
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Nagre-recruitPhase 2
- Vanderbilt Cancer Center, Nashville
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1
- SCRI Oncology Partners - Nashville, Nashville
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Vanderbilt-Ingram Cancer Center, Nashville
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Nagre-recruitPhase 2
- Greco-Hainsworth Centers for Research/Tennessee Oncology, Nashville
- SCRI Oncology Partners, Nashville
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Nagre-recruitPhase 3
- SCRI Oncology Partners, Nashville
E-Mindfulness Approaches for Living After Breast Cancer
Nagre-recruitPhase 3
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Tennessee Oncology PLLC, Nashville
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Nagre-recruitPhase 2
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- Investigative Site #102, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Nagre-recruitMaagang Phase 1
- Vanderbilt University Medical Center, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Nagre-recruitPhase 3
- SCRI Oncology Partners, Nashville
- Henry-Joyce Cancer Clinic, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Nagre-recruit
- Vanderbilt-Ingram Cancer Center, Nashville
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Nagre-recruitPhase 2
- Vanderbilt University, Nashville
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Nagre-recruitPhase 2
- Vanderbilt-Ingram Cancer Center, Nashville
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Nagre-recruitPhase 3
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Nagre-recruitPhase 1
- Sarah Cannon Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Nagre-recruitPhase 1/2
- Vanderbilt University Medical Center, Nashville
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Nagre-recruitPhase 2
- Vanderbilt University, Nashville
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Tennessee Oncology, PLLC, Nashville
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Nagre-recruitPhase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Nagre-recruitPhase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Tennessee Oncology, Nashville
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Nagre-recruitPhase 1
- Tennessee Oncology, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #6, Nashville
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Nagre-recruitObservasyonal na pag-aaral
- Nashville Breast Center, Nashville
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
Pag-aaral para sa Kanser sa Suso sa ibang lungsod
- New York City, NY136 pag-aaral
- Houston, TX126 pag-aaral
- Boston, MA112 pag-aaral
- Los Angeles, CA73 pag-aaral
- Edison, NJ68 pag-aaral
- St. Louis, MO64 pag-aaral
- Queens, NY64 pag-aaral
- Durham, NC64 pag-aaral
- Chicago, IL59 pag-aaral
- Philadelphia, PA56 pag-aaral
- Dallas, TX55 pag-aaral
- San Antonio, TX47 pag-aaral
Iba pang pag-aaral sa Nashville
- Non-Small Cell Lung Cancer97 pag-aaral
- Metastatic Cancer70 pag-aaral
- Colorectal Cancer69 pag-aaral
- Kanser (lahat ng uri)65 pag-aaral
- Kanser sa Ovary49 pag-aaral
- Kanser sa Prostate43 pag-aaral
- Kanser sa Baga40 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg39 pag-aaral
- Kanser sa Pancreas39 pag-aaral
- Kanser ng Endometrium38 pag-aaral
- Melanoma33 pag-aaral
- Multiple Myeloma32 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.